The present invention discloses novel pharmaceutical composition comprising a crystalline non-solvated raloxifene hydrochloride, having improved dissolution even with higher particle size of raloxifene hydrochloride having a mean particle size of at least about 35 microns & 90 percent of particles having about 60 to...

The present invention relates to an improved process for preparing methyl 4"-(4-methyl-6 (1-methyl-1H-benzimidazole-2-yl)-2-propyl-1H-benzimidazole-1–y1] biphenyl-2-carboxylate intermediate, which is further hydrolyzed to telmisartan. The present invention achieves the desired carboxylate intermediate in good yields...

Disclosed herein is an improved novel synthetic process for the preparation of Eprosartan, which comprises treating 2-n-butyl-4-formylimidazoIe of formula II with N-protecting group selected from the group consisting of C1-C4 alkyl ester derivative of methacrylic acid; C1-C4 alkyl ester derivative of crotonic acid; ...